KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

William Pao, Theresa Y. Wang, Gregory J. Riely, Vincent A. Miller, Qiulu Pan, Marc Ladanyi, Maureen F. Zakowski, Robert T. Heelan, Mark G. Kris, Harold E. Varmus

Research output: Contribution to journalArticlepeer-review

1406 Scopus citations

Fingerprint

Dive into the research topics of 'KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Biochemistry, Genetics and Molecular Biology

Keyphrases